Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-Current Deffered Revenue (2016 - 2025)

Adma Biologics (ADMA) has disclosed Non-Current Deffered Revenue for 11 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 9.18% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Dec 2025, down 9.18%, and an annual FY2025 reading of $1.4 million, down 9.18% over the prior year.
  • Non-Current Deffered Revenue was $1.4 million for Q4 2025 at Adma Biologics, down from $1.4 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $2.1 million in Q1 2021 and bottomed at $1.4 million in Q4 2025.
  • Average Non-Current Deffered Revenue over 5 years is $1.7 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue fell 6.42% in 2021, then fell 9.18% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $2.0 million in 2021, then decreased by 7.23% to $1.8 million in 2022, then dropped by 7.8% to $1.7 million in 2023, then fell by 8.46% to $1.5 million in 2024, then fell by 9.18% to $1.4 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for ADMA at $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.5 million in Q2 2025.